|
|
|
|
|
|
Your Position : Home
>> R&D Center >> About R&D Center
|
|
|
The Konzern Research and Development Center was established in January 2003 by one of the founder, Ms. Liu Minhua. On October 8, 2003, Konzern committed to jointly establish a research and development center at Nanhua University in Hengyang City, Hunan Province, China, together with the Pharmaceutical Research Institute of Nanhua University. Under the agreement governing the creation of the center, Konzern contributes funds in return for ownership of the new medicines developed by the center.
The Company has obtained four patents for the production methods of products, which the company developed and or controlled.We aso have seven patents pending and hope to roll out new products in the near future.
In 2004, Konzern signed a contract with Nanhua University to develop the new medicines together, where the company moved Konzern R&D center to the Medicine Institute of Nanhua University.
In 2005, the company adjusted the organization and further cleared the responsibilities of the R&D center.
• Participating in the drafting of the developing plan of the company;
• Planning and setting up the research projects;
• Introducing and selecting the research projects;
• Administrating and evaluating the on-going projects;
• Reviewing and approving the R&D expenses
• Co-operating with the Sales Department for the marketing of the new products;
• Reporting the progress of the new projects to related admin department in the city and the province;
• Maintaining working relations with other research institutes
In the short term our R&D team focuses on the developing and marketing the nutritional supplements; in the mid term, we aim to develop prescription and OTC drugs; where as in the longer term, we are dedicated to develop anti-tumor traditional Chinese medicines.
On July 7, 2006, China Medicine also created a PRC joint-venture with Guangzhou Ji'nan Science & Technology Industrial Group ("JSIG") and Mr. Dongsheng Yao. The purpose of the new company, Guangzhou Co-win Bioengineering Co., Ltd. (“Co-Win”), is to develop applications for aflatoxin-detoxifizyme, or ADTZ, an enzyme that can eliminate aflatoxin from food and animal feed. Aflatoxin, a toxic substance that causes liver, stomach and lung cancers in animals and humans, is produced by the common aspergillus fungus and frequently affects cereal grains, oilseeds, spices, peanuts and acorns.
|
|